Analysis of predictive factors influencing dupilumab continuation rate in adult patients with atopic dermatitis: results from an Italian multicenter study

References

• Weidinger S, Beck LA, Bieber T, et al. Atopic dermatitis. Nat Rev Dis Primers. 2018;4(1):1. doi:10.1038/s41572-018-0001-z.
   PubMed Web of Science ®Google Scholar
• Gori N, Chiricozzi A, Marsili F, et al. National information campaign revealed disease characteristic and burden in adult patients suffering from atopic dermatitis. J Clin Med. 2022;11(17):5204. doi:10.3390/jcm11175204.
   PubMed Web of Science ®Google Scholar
• Talamonti M, Galluzzo M, Silvaggio D, et al. Quality of life and psychological impact in patients with atopic dermatitis. J Clin Med. 2021;10(6):1298. doi:10.3390/jcm10061298.
   PubMed Web of Science ®Google Scholar
• Siegels D, Heratizadeh A, Abraham S, et al. European academy of allergy, clinical immunology atopic dermatitis guideline group. Systemic treatments in the management of atopic dermatitis: a systematic review and meta-analysis. Allergy. 2021;76(4):1053–7. doi:10.1111/all.14631.
   PubMed Web of Science ®Google Scholar
• Simpson EL, Bieber T, Guttman-Yassky E, et al. SOLO 1 and SOLO 2 investigators: two phase 3 trials of dupilumab versus placebo in atopic dermatitis. N Engl J Med. 2016;375(24):2335–2348. doi:10.1056/NEJMoa1610020.
   PubMed Web of Science ®Google Scholar
• Blauvelt A, de Bruin-Weller M, Gooderham M, et al. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial. Lancet. 2017;389(10086):2287–2303. doi:10.1016/S0140-6736(17)31191-1.
   PubMed Web of Science ®Google Scholar
• de Bruin-Weller M, Thaçi D, Smith CH, et al. Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin a or when this treatment is medically inadvisable: a placebo-controlled, randomized phase III clinical trial (LIBERTY AD CAFÉ). Br J Dermatol. 2018;178(5):1083–1101. doi:10.1111/bjd.16156.
   PubMed Web of Science ®Google Scholar
• Lauvelt A, Wollenberg A, Eichenfield LF, et al. No increased risk of overall infection in adults with moderate-to-severe atopic dermatitis treated for up to 4 years with dupilumab. Adv Ther. 2023;40(1):367–380. doi:10.1007/s12325-022-02322-y.
   PubMed Web of Science ®Google Scholar
• Fargnoli MC, Esposito M, Ferrucci S, et al. A 48-week update of a multicentre real-life experience of dupilumab in adult patients with moderate-to-severe atopic dermatitis. J Dermatolog Treat. 2022;33(2):1146–1149. doi:10.1080/09546634.2020.1773379.
   PubMed Web of Science ®Google Scholar
• Khosravi H, Zhang S, Anderson AM, et al. Dupilumab drug survival, treatment failures, and insurance approval at a tertiary care center in the United States. J Am Acad Dermatol. 2020;82(4):1023–1024. doi:10.1016/j.jaad.2019.12.034.
   PubMed Web of Science ®Google Scholar
• Silverberg JI, Guttman-Yassky E, Gadkari A, et al. Real-world persistence with dupilumab among adults with atopic dermatitis. Ann Allergy Asthma Immunol. 2021;126(1):40–45. doi:10.1016/j.anai.2020.07.026.
   PubMed Web of Science ®Google Scholar
• Van den Reek JMPA, Kievit W, Gniadecki R, et al. Drug survival studies in dermatology: principles, purposes, and pitfalls. J Invest Dermatol. 2015;135(7):1–5. doi:10.1038/jid.2015.171.
   PubMed Web of Science ®Google Scholar
• Silvestre Salvador JF, Romero-Pérez D, Encabo-Durán B. Atopic dermatitis in adults: a diagnostic challenge. J Investig Allergol Clin Immunol. 2017;27(2):78–88. doi:10.18176/jiaci.0138.
   PubMed Web of Science ®Google Scholar
• Georgakopoulos JR, Felfeli T, Drucker AM, et al. Two-year efficacy, safety, and drug survival of dupilumab for atopic dermatitis: a real-world Canadian multicenter retrospective study. JAAD Int. 2021;4:67–69. doi:10.1016/j.jdin.2021.06.001.
   PubMedGoogle Scholar
• Spekhorst LS, De Graaf M, Zuithoff NPA, et al. Dupilumab drug survival and associated predictors in patients with moderate to severe atopic dermatitis: long-term results from the daily practice BioDay registry. JAMA Dermatol. 2022;158(9):1048. doi:10.1001/jamadermatol.2022.3014.
   PubMed Web of Science ®Google Scholar
• Spekhorst LS, Ariëns LF, Schaft J, et al. Two-year drug survival of dupilumab in a large cohort of difficult-to-treat adult atopic dermatitis patients compared to cyclosporine a and methotrexate: results from the BioDay registry. Allergy. 2020;75(9):2376–2379. doi:10.1111/all.14324.
   PubMed Web of Science ®Google Scholar
• Dal Bello G, Maurelli M, Schena D, et al. Drug survival of dupilumab compared to cyclosporin in moderate-to-severe atopic dermatitis patients. Dermatol Ther. 2020;33(6):e13979.
   PubMed Web of Science ®Google Scholar
• Pezzolo E, Rossi M, Caroppo F, et al. Long-term drug survival of dupilumab and associated predictors in moderate-to-­severe atopic dermatitis: a real-world prospective cohort study. Acad Dermatol Venereol. 2023;37(6):18889. doi:10.1111/jdv.18889.
   Google Scholar
• Gori N, Chiricozzi A, Malvaso D, et al. Successful combination of systemic agents for the treatment of atopic dermatitis resistant to dupilumab therapy. Dermatology. 2021;237(4):535–541. doi:10.1159/000512890.
   PubMed Web of Science ®Google Scholar
• Narla S, Silverberg JI, Simpson EL. Response to the article by Narla et al “Management of inadequate response and adverse effects to dupilumab in atopic dermatitis”. J Am Acad Dermatol. 2022;86(3):628–636. doi:10.1016/j.jaad.2021.06.017.
   PubMed Web of Science ®Google Scholar
• Kojanova M, Tanczosova M, Strosova D, et al. Dupilumab for the treatment of atopic dermatitis: real-world data from the Czech Republic BIOREP registry. J Dermatolog Treat. 2022;33(5):2578–2586. doi:10.1080/09546634.2022.2043545.
   PubMed Web of Science ®Google Scholar
• Gori N, Chiricozzi A, Peris K. Management of inadequate response and adverse effects to dupilumab in atopic dermatitis. J Am Acad Dermatol. 2023;88(1):e65–e66. doi:10.1016/j.jaad.2022.09.055.
   PubMed Web of Science ®Google Scholar
• Napolitano M, Mariano M, Cristaudo A, et al. Drug survival analysis of dupilumab and cyclosporin in patients with atopic dermatitis: a multicenter study. J Dermatolog Treat. 2022;33(5):2670–2673. doi:10.1080/09546634.2022.2067818.
   PubMed Web of Science ®Google Scholar
• Nettis E, Fabbrocini G, Ortoncelli M, et al. Long-term effectiveness of dupilumab up to 52 weeks in atopic dermatitis in 253 adult patients. Br J Dermatol. 2021;184(3):561–563. doi:10.1111/bjd.19577.
   PubMed Web of Science ®Google Scholar
• Patruno C, Potestio L, Fabbrocini G, et al. Dupilumab dose spacing after initial successful treatment or adverse events in adult patients with atopic dermatitis: a retrospective analysis. Dermatol Ther. 2022;35(12):e15933. doi:10.1111/dth.15933.
   PubMed Web of Science ®Google Scholar